Based on our findings and previous studies, plasma S100A1 protein has the potential to serve as an inclusion criterion for future clinical diagnostic trials in AIS, and lowering the level of this protein may be a novel therapeutic target to improve their severity. Here, S100A1 is linked to androgen insensitivity syndrome.